Several new treatments are transforming diabetes treatment, with Retatrutide, Cagrillintide, Tirzepatide, and Semaglutide emerging as promising options. Retatrutide, a double GIP and GLP-1 target stimulant, exhibits substantial fat reduction along with improved glucose regulation. Cagrillintide,